Penil Kanserlere Yaklaşım
Özet
Penis kanseri, Human Papilloma Virus (HPV) ve fimozis gibi temel risk faktörleriyle ilişkili, nadir görülen agresif bir malignitedir. En yaygın histolojik tip olan skuamöz hücreli karsinomun (SCC) klinik bulguları heterojen olup, kesin tanı penisteki lezyonun histopatolojik incelemesiyle konur. Evrelemede TNM sınıflandırması tercih edilirken; primer tümörün invazyon derinliği, inguinal lenf nodlarının durumu ve uzak metastaz varlığı prognozu belirleyen en kritik unsurlardır. Tedavi stratejileri klinik evreye göre şekillenir ve onkolojik prensiplerden ödün vermeden organ koruyucu yaklaşımlar (lazer, topikal kemoterapi, parsiyel cerrahi, radyoterapi) ön planda tutulur; ileri evrelerde ise radikal cerrahi ve kemoterapi uygulanır. Nükslerin erken tespiti ve hastalıksız sağ kalım için primer tümör ve lenf nodlarının en az 5 yıl boyunca düzenli takibi hayati önem taşımaktadır.
Penile cancer is a rare yet aggressive malignancy closely associated with key risk factors such as Human Papilloma Virus (HPV) and phimosis. The clinical presentation of squamous cell carcinoma (SCC), which is the most common histological type, is highly heterogeneous, and a definitive diagnosis relies entirely on the histopathological evaluation of the penile lesion. While the TNM classification system is utilized for staging, the depth of invasion of the primary tumor, the status of the inguinal lymph nodes, and the presence of distant metastases constitute the most critical prognostic factors. Treatment strategies are tailored according to the clinical stage, prioritizing organ-preserving approaches (such as laser therapies, topical chemotherapy, partial surgery, and radiotherapy) without compromising oncological principles, whereas radical surgery and systemic chemotherapy are mandatory in advanced stages. Regular and meticulous follow-up of both the primary tumor site and the lymph nodes for at least 5 years is of vital importance for the early detection of recurrences and for ensuring long-term disease-free survival.
Referanslar
Backes DM, Kurman RJ, Pimenta JM, Smith JS. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control. 2009;20(4):449-57.
Chaux A, Netto GJ, Rodríguez IM, Barreto JE, Oertell J, Ocampos S, et al. Epidemiologic profile, sexual history, pathologic features, and human papillomavirus status of 103 patients with penile carcinoma. World J Urol. 2013;31(4):861-7.
Cancer incidence in five continents. Volume VIII. IARC Sci Publ. 2002(155):1-781.
Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24 Suppl 3:S3/11-25.
Gloeckler-Ries LA HB, Edwards BK. . Cancer statistics review 1973–1987. National Cancer Institute, National Institutes of Health Publication No. 90-2789. [ed; Bethesda, MD: National Institutes of Health] 1990.
Barnholtz-Sloan JS, Maldonado JL, Pow-sang J, Giuliano AR. Incidence trends in primary malignant penile cancer. Urol Oncol. 2007;25(5):361-7.
Hartwig S, Syrjänen S, Dominiak-Felden G, Brotons M, Castellsagué X. Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. BMC Cancer. 2012;12:30.
Tsen HF, Morgenstern H, Mack T, Peters RK. Risk factors for penile cancer: results of a population-based case-control study in Los Angeles County (United States). Cancer Causes Control. 2001;12(3):267-77.
Koifman L, Vides AJ, Koifman N, Carvalho JP, Ornellas AA. Epidemiological aspects of penile cancer in Rio de Janeiro: evaluation of 230 cases. Int Braz J Urol. 2011;37(2):231-40; discussion 40-3.
Van Howe RS, Hodges FM. The carcinogenicity of smegma: debunking a myth. J Eur Acad Dermatol Venereol. 2006;20(9):1046-54.
Plaut ABJ, Kohn-Speyer AC. The Carcinogenic Action of Smegma. Science. 1947;105 2728:391-2.
Kayes O, Ahmed HU, Arya M, Minhas S. Molecular and genetic pathways in penile cancer. Lancet Oncol. 2007;8(5):420-9.
Muñoz N, Castellsagué X, Berrington de González A, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24 Suppl 3:S3/1-10.
O.W. Hakenberg EC, S. Minhas, A. Necchi, C. Protzel, N. Watkin. . O.W. Hakenberg, E. Compérat, S. Minhas, A. Necchi, C. Protzel, N. Watkin. European Association of Urology: EAU Guidelines on Penile Cancer: update March 2018.
Nordenvall C, Chang ET, Adami HO, Ye W. Cancer risk among patients with condylomata acuminata. Int J Cancer. 2006;119(4):888-93.
Lont AP, Kroon BK, Horenblas S, Gallee MP, Berkhof J, Meijer CJ, et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer. 2006;119(5):1078-81.
Newman PA, Logie CH, Doukas N, Asakura K. HPV vaccine acceptability among men: a systematic review and meta-analysis. Sex Transm Infect. 2013;89(7):568-74.
Nasca MR, Innocenzi D, Micali G. Penile cancer among patients with genital lichen sclerosus. J Am Acad Dermatol. 1999;41(6):911-4.
Schoen EJ, Oehrli M, Colby C, Machin G. The highly protective effect of newborn circumcision against invasive penile cancer. Pediatrics. 2000;105(3):E36.
Stern RS. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012;66(4):553-62.
Daling JR, Sherman KJ, Hislop TG, Maden C, Mandelson MT, Beckmann AM, et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol. 1992;135(2):180-9.
McIntyre M, Weiss A, Wahlquist A, Keane T, Clarke H, Savage S. Penile cancer: an analysis of socioeconomic factors at a southeastern tertiary referral center. Can J Urol. 2011;18(1):5524-8.
Benard VB, Johnson CJ, Thompson TD, Roland KB, Lai SM, Cokkinides V, et al. Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer. 2008;113(10 Suppl):2910-8.
Ulff-Møller CJ, Simonsen J, Frisch M. Marriage, cohabitation and incidence trends of invasive penile squamous cell carcinoma in Denmark 1978-2010. Int J Cancer. 2013;133(5):1173-9.
Dillner J, von Krogh G, Horenblas S, Meijer CJ. Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl. 2000(205):189-93.
Pettaway CA, Lance RS, Davis JW, editors. Tumors of the Penis2012.
Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ. Penile cancer: epidemiology, pathogenesis and prevention. World J Urol. 2009;27(2):141-50.
Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol. 2004;193(1):35-44.
Wieland U, Jurk S, Weissenborn S, Krieg T, Pfister H, Ritzkowsky A. Erythroplasia of queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. J Invest Dermatol. 2000;115(3):396-401.
Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136(10):1266-97.
Hoekstra RJ, Trip EJ, Ten Kate FJ, Horenblas S, Lock MT. Penile intraepithelial neoplasia: Nomenclature, incidence and progression to malignancy in the Netherlands. Int J Urol. 2019;26(3):353-7.
Schellhammer PF, Jordan GH, Robey EL, Spaulding JT. Premalignant lesions and nonsquamous malignancy of the penis and carcinoma of the scrotum. Urol Clin North Am. 1992;19(1):131-42.
Mikhail GR. Cancers, precancers, and pseudocancers on the male genitalia. A review of clinical appearances, histopathology, and management. J Dermatol Surg Oncol. 1980;6(12):1027-35.
Lucia MS, Miller GJ. Histopathology of malignant lesions of the penis. Urol Clin North Am. 1992;19(2):227-46.
Kaye V, Zhang G, Dehner LP, Fraley EE. Carcinoma in situ of penis. Is distinction between erythroplasia of Queyrat and Bowen's disease relevant? Urology. 1990;36(6):479-82.
Burgers JK, Badalament RA, Drago JR. Penile cancer. Clinical presentation, diagnosis, and staging. Urol Clin North Am. 1992;19(2):247-56.
Afonso LA, Cordeiro TI, Carestiato FN, Ornellas AA, Alves G, Cavalcanti SM. High Risk Human Papillomavirus Infection of the Foreskin in Asymptomatic Men and Patients with Phimosis. J Urol. 2016;195(6):1784-9.
Lont AP, Besnard AP, Gallee MP, van Tinteren H, Horenblas S. A comparison of physical examination and imaging in determining the extent of primary penile carcinoma. BJU Int. 2003;91(6):493-5.
Hanchanale V, Yeo L, Subedi N, Smith J, Wah T, Harnden P, et al. The accuracy of magnetic resonance imaging (MRI) in predicting the invasion of the tunica albuginea and the urethra during the primary staging of penile cancer. BJU Int. 2016;117(3):439-43.
Bozzini G, Provenzano M, Romero Otero J, Margreiter M, Garcia Cruz E, Osmolorskij B, et al. Role of Penile Doppler US in the Preoperative Assessment of Penile Squamous Cell Carcinoma Patients: Results From a Large Prospective Multicenter European Study. Urology. 2016;90:131-5.
Cubilla AL, Reuter V, Velazquez E, Piris A, Saito S, Young RH. Histologic classification of penile carcinoma and its relation to outcome in 61 patients with primary resection. Int J Surg Pathol. 2001;9(2):111-20.
Slaton JW, Morgenstern N, Levy DA, Santos MW, Jr., Tamboli P, Ro JY, et al. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol. 2001;165(4):1138-42.
Krishna RP, Sistla SC, Smile R, Krishnan R. Sonography: an underutilized diagnostic tool in the assessment of metastatic groin nodes. J Clin Ultrasound. 2008;36(4):212-7.
Mueller-Lisse UG, Scher B, Scherr MK, Seitz M. Functional imaging in penile cancer: PET/computed tomography, MRI, and sentinel lymph node biopsy. Curr Opin Urol. 2008;18(1):105-10.
Leijte JA, Graafland NM, Valdés Olmos RA, van Boven HH, Hoefnagel CA, Horenblas S. Prospective evaluation of hybrid 18F-fluorodeoxyglucose positron emission tomography/computed tomography in staging clinically node-negative patients with penile carcinoma. BJU Int. 2009;104(5):640-4.
Graafland NM, Lam W, Leijte JA, Yap T, Gallee MP, Corbishley C, et al. Prognostic factors for occult inguinal lymph node involvement in penile carcinoma and assessment of the high-risk EAU subgroup: a two-institution analysis of 342 clinically node-negative patients. Eur Urol. 2010;58(5):742-7.
Souillac I, Rigaud J, Ansquer C, Marconnet L, Bouchot O. Prospective evaluation of (18)F-fluorodeoxyglucose positron emission tomography-computerized tomography to assess inguinal lymph node status in invasive squamous cell carcinoma of the penis. J Urol. 2012;187(2):493-7.
Ornellas AA, Kinchin EW, Nóbrega BL, Wisnescky A, Koifman N, Quirino R. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol. 2008;97(6):487-95.
Zhu Y, Zhang SL, Ye DW, Yao XD, Jiang ZX, Zhou XY. Predicting pelvic lymph node metastases in penile cancer patients: a comparison of computed tomography, Cloquet's node, and disease burden of inguinal lymph nodes. Onkologie. 2008;31(1-2):37-41.
Zhu Y, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, et al. The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer. J Urol. 2008;180(5):2019-23.
Brierley J, Gospodarowicz M, Wittekind C, et al.,. Brierley, J., Gospodarowicz M, Wittekind C, et al., TNM Classification of Malignant Tumours, 8th Edn. 2016.
Cubilla AL, Barreto J, Caballero C, Ayala G, Riveros M. Pathologic features of epidermoid carcinoma of the penis. A prospective study of 66 cases. Am J Surg Pathol. 1993;17(8):753-63.
Tobias-Machado M, Tavares A, Ornellas AA, Molina WR, Jr., Juliano RV, Wroclawski ER. Video endoscopic inguinal lymphadenectomy: a new minimally invasive procedure for radical management of inguinal nodes in patients with penile squamous cell carcinoma. J Urol. 2007;177(3):953-7; discussion 8.
Winters BR, Mossanen M, Holt SK, Lin DW, Wright JL. Predictors of Nodal Upstaging in Clinical Node Negative Patients With Penile Carcinoma: A National Cancer Database Analysis. Urology. 2016;96:29-34.
Velazquez EF, Soskin A, Bock A, Codas R, Cai G, Barreto JE, et al. Epithelial abnormalities and precancerous lesions of anterior urethra in patients with penile carcinoma: a report of 89 cases. Mod Pathol. 2005;18(7):917-23.
Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol. 2008;54(1):161-8.
Alnajjar HM, Lam W, Bolgeri M, Rees RW, Perry MJ, Watkin NA. Treatment of carcinoma in situ of the glans penis with topical chemotherapy agents. Eur Urol. 2012;62(5):923-8.
Frimberger D, Hungerhuber E, Zaak D, Waidelich R, Hofstetter A, Schneede P. Penile carcinoma. Is Nd:YAG laser therapy radical enough? J Urol. 2002;168(6):2418-21; discussion 21.
Bandieramonte G, Colecchia M, Mariani L, Lo Vullo S, Pizzocaro G, Piva L, et al. Peniscopically controlled CO2 laser excision for conservative treatment of in situ and T1 penile carcinoma: report on 224 patients. Eur Urol. 2008;54(4):875-82.
Philippou P, Shabbir M, Malone P, Nigam R, Muneer A, Ralph DJ, et al. Conservative surgery for squamous cell carcinoma of the penis: resection margins and long-term oncological control. J Urol. 2012;188(3):803-8.
Piva L, Nicolai N, Di Palo A, Milani A, Merson M, Salvioni R, et al. [Therapeutic alternatives in the treatment of class T1N0 squamous cell carcinoma of the penis: indications and limitations]. Arch Ital Urol Androl. 1996;68(3):157-61.
Colecchia M, Nicolai N, Secchi P, Bandieramonte G, Paganoni AM, Sangalli LM, et al. pT1 penile squamous cell carcinoma: a clinicopathologic study of 56 cases treated by CO2 laser therapy. Anal Quant Cytol Histol. 2009;31(3):153-60.
Schlenker B, Tilki D, Seitz M, Bader MJ, Reich O, Schneede P, et al. Organ-preserving neodymium-yttrium-aluminium-garnet laser therapy for penile carcinoma: a long-term follow-up. BJU Int. 2010;106(6):786-90.
Meijer RP, Boon TA, van Venrooij GE, Wijburg CJ. Long-term follow-up after laser therapy for penile carcinoma. Urology. 2007;69(4):759-62.
Rothenberger KH, Hofstetter A. [Laser therapy of penile carcinoma]. Urologe A. 1994;33(4):291-4.
Mohs FE, Snow SN, Larson PO. Mohs micrographic surgery for penile tumors. Urol Clin North Am. 1992;19(2):291-304.
Machan M, Brodland D, Zitelli J. Penile Squamous Cell Carcinoma: Penis-Preserving Treatment With Mohs Micrographic Surgery. Dermatol Surg. 2016;42(8):936-44.
Shindel AW, Mann MW, Lev RY, Sengelmann R, Petersen J, Hruza GJ, et al. Mohs micrographic surgery for penile cancer: management and long-term followup. J Urol. 2007;178(5):1980-5.
Hadway P, Corbishley CM, Watkin NA. Total glans resurfacing for premalignant lesions of the penis: initial outcome data. BJU Int. 2006;98(3):532-6.
Ayres, B., et al., Glans resurfacing – a new penile preserving option for superficially invasive penile cancer. Eur Urol Suppl, 2011. 10: 340.
Li J, Zhu Y, Zhang SL, Wang CF, Yao XD, Dai B, et al. Organ-sparing surgery for penile cancer: complications and outcomes. Urology. 2011;78(5):1121-4.
Austoni E., et al. Reconstructive surgery for penile cancer with preservation of sexual function. Eur Urol Suppl, 2008. 7: 116 (Abstract #183).
Lümmen G, Sperling H, Pietsch M, Otto T, Rübben H. [Treatment and follow-up of patients with squamous epithelial carcinoma of the penis]. Urologe A. 1997;36(2):157-61.
Khezri AA, Dunn M, Smith PJ, Mitchell JP. Carcinoma of the penis. Br J Urol. 1978;50(4):275-9.
Modig H, Duchek M, Sjödin JG. Carcinoma of the penis. Treatment by surgery or combined bleomycin and radiation therapy. Acta Oncol. 1993;32(6):653-5.
Djajadiningrat RS, van Werkhoven E, Meinhardt W, van Rhijn BW, Bex A, van der Poel HG, et al. Penile sparing surgery for penile cancer-does it affect survival? J Urol. 2014;192(1):120-5.
Zouhair A, Coucke PA, Jeanneret W, Douglas P, Do HP, Jichlinski P, et al. Radiation therapy alone or combined surgery and radiation therapy in squamous-cell carcinoma of the penis? Eur J Cancer. 2001;37(2):198-203.
Crook J, Ma C, Grimard L. Radiation therapy in the management of the primary penile tumor: an update. World J Urol. 2009;27(2):189-96.
de Crevoisier R, Slimane K, Sanfilippo N, Bossi A, Albano M, Dumas I, et al. Long-term results of brachytherapy for carcinoma of the penis confined to the glans (N- or NX). Int J Radiat Oncol Biol Phys. 2009;74(4):1150-6.
Crook J, Jezioranski J, Cygler JE. Penile brachytherapy: technical aspects and postimplant issues. Brachytherapy. 2010;9(2):151-8.
Delaunay B, Soh PN, Delannes M, Riou O, Malavaud B, Moreno F, et al. Brachytherapy for penile cancer: efficacy and impact on sexual function. Brachytherapy. 2014;13(4):380-7.
Crook J. Radiation therapy for cancer of the penis. Urol Clin North Am. 2010;37(3):435-43.
Hasan S, Francis A, Hagenauer A, Hirsh A, Kaminsky D, Traughber B, et al. The role of brachytherapy in organ preservation for penile cancer: A meta-analysis and review of the literature. Brachytherapy. 2015;14(4):517-24.
Cordoba A, Escande A, Lopez S, Mortier L, Mirabel X, Coche-Déqueant B, et al. Low-dose brachytherapy for early stage penile cancer: a 20-year single-institution study (73 patients). Radiat Oncol. 2016;11:96.
Azrif M, Logue JP, Swindell R, Cowan RA, Wylie JP, Livsey JE. External-beam radiotherapy in T1-2 N0 penile carcinoma. Clin Oncol (R Coll Radiol). 2006;18(4):320-5.
Smith Y, Hadway P, Biedrzycki O, Perry MJ, Corbishley C, Watkin NA. Reconstructive surgery for invasive squamous carcinoma of the glans penis. Eur Urol. 2007;52(4):1179-85.
Gotsadze D, Matveev B, Zak B, Mamaladze V. Is conservative organ-sparing treatment of penile carcinoma justified? Eur Urol. 2000;38(3):306-12.
Paoli J, Ternesten Bratel A, Löwhagen GB, Stenquist B, Forslund O, Wennberg AM. Penile intraepithelial neoplasia: results of photodynamic therapy. Acta Derm Venereol. 2006;86(5):418-21.
Horenblas S. Lymphadenectomy in penile cancer. Urol Clin North Am. 2011;38(4):459-69, vi-vii.
Protzel C, Alcaraz A, Horenblas S, Pizzocaro G, Zlotta A, Hakenberg OW. Lymphadenectomy in the surgical management of penile cancer. Eur Urol. 2009;55(5):1075-88.
Windahl T, Andersson SO. Combined laser treatment for penile carcinoma: results after long-term followup. J Urol. 2003;169(6):2118-21.
van Bezooijen BP, Horenblas S, Meinhardt W, Newling DW. Laser therapy for carcinoma in situ of the penis. J Urol. 2001;166(5):1670-1.
Rosevear HM, Williams H, Collins M, Lightfoot AJ, Coleman T, Brown JA. Utility of ¹⁸F-FDG PET/CT in identifying penile squamous cell carcinoma metastatic lymph nodes. Urol Oncol. 2012;30(5):723-6.
Saisorn I, Lawrentschuk N, Leewansangtong S, Bolton DM. Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma. BJU Int. 2006;97(6):1225-8.
Koifman L, Hampl D, Koifman N, Vides AJ, Ornellas AA. Radical open inguinal lymphadenectomy for penile carcinoma: surgical technique, early complications and late outcomes. J Urol. 2013;190(6):2086-92.
Yao K, Tu H, Li YH, Qin ZK, Liu ZW, Zhou FJ, et al. Modified technique of radical inguinal lymphadenectomy for penile carcinoma: morbidity and outcome. J Urol. 2010;184(2):546-52.
La-Touche S, Ayres B, Lam W, Alnajjar HM, Perry M, Watkin N. Trial of ligation versus coagulation of lymphatics in dynamic inguinal sentinel lymph node biopsy for staging of squamous cell carcinoma of the penis. Ann R Coll Surg Engl. 2012;94(5):344-6.
Kumar V, Sethia KK. Prospective study comparing video-endoscopic radical inguinal lymph node dissection (VEILND) with open radical ILND (OILND) for penile cancer over an 8-year period. BJU Int. 2017;119(4):530-4.
Lughezzani G, Catanzaro M, Torelli T, Piva L, Biasoni D, Stagni S, et al. The relationship between characteristics of inguinal lymph nodes and pelvic lymph node involvement in penile squamous cell carcinoma: a single institution experience. J Urol. 2014;191(4):977-82.
Lucky MA, Rogers B, Parr NJ. Referrals into a dedicated British penile cancer centre and sources of possible delay. Sex Transm Infect. 2009;85(7):527-30.
Nicolai N, Sangalli LM, Necchi A, Giannatempo P, Paganoni AM, Colecchia M, et al. A Combination of Cisplatin and 5-Fluorouracil With a Taxane in Patients Who Underwent Lymph Node Dissection for Nodal Metastases From Squamous Cell Carcinoma of the Penis: Treatment Outcome and Survival Analyses in Neoadjuvant and Adjuvant Settings. Clin Genitourin Cancer. 2016;14(4):323-30.
Sharma P, Djajadiningrat R, Zargar-Shoshtari K, Catanzaro M, Zhu Y, Nicolai N, et al. Adjuvant chemotherapy is associated with improved overall survival in pelvic node-positive penile cancer after lymph node dissection: a multi-institutional study. Urol Oncol. 2015;33(11):496.e17-23.
Pizzocaro G, Nicolai N, Milani A. Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol. 2009;55(3):546-51.
Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol. 1988;27(6b):823-4.
Pizzocaro G, Piva L, Bandieramonte G, Tana S. Up-to-date management of carcinoma of the penis. Eur Urol. 1997;32(1):5-15.
Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28(24):3851-7.
Giannatempo P., et al. Survival analyses of adjuvant or neoadjuvant combination of a taxane plus cisplatin and 5-fluorouracil (T-PF) in patients with bulky nodal metastases from squamous cell carcinoma of the penis (PSCC): Results of a single high-volume center. J Clin Oncol, 2014. 32: 5.
Pond GR, Di Lorenzo G, Necchi A, Eigl BJ, Kolinsky MP, Chacko RT, et al. Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. Urol Oncol. 2014;32(4):501-8.
Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol. 2007;177(4):1335-8.
Power DG, Galvin DJ, Cuffe S, McVey GP, Mulholland PJ, Farrelly C, et al. Cisplatin and gemcitabine in the management of metastatic penile cancer. Urol Oncol. 2009;27(2):187-90.
Necchi A, Giannatempo P, Lo Vullo S, Raggi D, Nicolai N, Colecchia M, et al. Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. Clin Genitourin Cancer. 2016;14(3):231-6.
Carthon BC, Ng CS, Pettaway CA, Pagliaro LC. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int. 2014;113(6):871-7.
